, and whose primary purpose was "treatment" were included in the final analysis. Trials were categorized according to cancer type and other registration information.
R adiotherapy is one of the cornerstone treatment modalities for cancer. It can be used alone or in combination with chemotherapy, surgery, or both. 1 As many as 50% of patients with cancer receive radiotherapy. 2 Many important advances in radiotherapy have emerged in recent years, including intensity-modulated radiotherapy, stereotactic ablative radiotherapy, 3-5 tomotherapy, and particle beam radiotherapy. 6, 7 However, aside from individual reports on the results of clinical trials involving radiotherapy, little is known about contemporary trials evaluating radiotherapy and its ability to advance clinical care. In 2004, the International Committee of Medical Journal Editors announced a policy as a prerequisite for publication that requires the registration of clinical trials before the enrollment of participants. 8 ClinicalTrials.gov is the most robust of the international registries for clinical trials and represents a unique resource for exploring clinical trials that have been registered worldwide. Presently, ClinicalTrials.gov contains detailed information on more than 240 000 clinical research studies conducted in more than 200 countries. 9 For this study, we examined all of the interventional oncology studies registered on ClinicalTrials.gov as of May 8, 2017 . We compared the fundamental characteristics of trials focusing on radiotherapy with the characteristics of other nonradiotherapy oncological trials; then, we evaluated the changes over time.
Methods

Data Source and Study Sample
We downloaded the records of all 243 758 clinical studies registered on ClinicalTrials.gov as of May 8, 2017 , using the database of the Aggregate Analysis of ClinicalTrials.gov (to see this database as well as data definitions and data dictionaries, go to the Clinical Trials Transformation Initiative website at https://www.ctti -clinicaltrials.org/aact-database). 9 We restricted our selection to interventional trials registered between June 1, 2007, and May 8, 2017 , whose "primary purpose" was "treatment" (N = 105 994; Figure 1 ). This study was submitted to the institutional review board of Sun Yat-sen University Cancer Center and was found not to constitute human subjects research. Two oncologists (X.L. and Y.Z.) independently identified the oncological trials, and a third oncologist (L.-L.T.) adjudicated any disagreements. Trials were then categorized according to cancer type, identified by the term condition, brief title, or official title. If the disease type was not clear, other registration information (eg, eligibility and detailed description) was reviewed. Trials that included 2 or more cancer types were grouped into a "multiple neoplasm" category. Similar methods were used to classify these studies into radiotherapy trials or other oncological trials.
We defined radiotherapy trials as studies that (1) added radiotherapy to the standard of care; (2) compared any treatment regimens with or without radiotherapy; (3) investigated novel radiotherapy regimes, such as radiotherapy techniques, volumes, doses, or fractionations; (4) compared different radiotherapy regimens; and (5) assessed interventions for radiotherapy-associated complications. We did not deem trials comparing radiotherapy with or without other treatment modalities or imaging as radiotherapy trials because such trials do not address the optimization of radiotherapy use in the clinic.
Study Variables
We examined these 9 dimensions for each trial: (1) registration before participant enrollment, as required by the International Committee of Medical Journal Editors; (2) presence or absence of a data monitoring committee (DMC); (3) phase of the trial; (4) number of treatment arms; (5) blinding and (6) allocation methods-randomized or nonrandomized; (7) sample size; (8) funding source; and (9) details of the study site.
We used methods described in previous studies [10] [11] [12] . A higher proportion of radiotherapy trials than other oncological trials were conducted for patients with genitourinary cancer (19.3% vs 7.8%; P < .001), lung cancer (13.1% vs 8.2%; P < .001), and head and neck cancer (7.8% vs 3.9%; P < .001), whereas a lower proportion of radiotherapy trials than other oncological trials were conducted for patients with hematological malignant neoplasm (2.5% vs 21.6%; P < .001) ( Figure 3 ). These observations are consistent with the clinical oncology practice in tumor types for which radiotherapy is the primary treatment modality. 
Results
Characteristics of Radiotherapy Trials and Other Oncological Trials
Chronological Shifts in Radiotherapy Trial Characteristics
Discussion
To our knowledge, this study is the first comprehensive study to assess the critical characteristics of registered radiotherapy trials. Our study helps us to better understand the current state of radiotherapy trials and provides insights for future development.
Radiotherapy is an indispensable treatment modality for many cancers, but radiotherapy trials account for only a minority (1378 of 25 907 [5.3%]) of all oncological trials registered on ClinicalTrials.gov. In recent years, multiple technological and biological advances have changed the landscape of radiation oncology. 1 The clinical gain of improved radiation dosimetry from innovative radiotherapy techniques ought to be tested and proven in clinical trials. However, a systematic analysis of 454 phase 3 randomized clinical trials involving radiotherapy from 1993 to 2016 found that intensitymodulated radiotherapy was used in only 1.3% of trial arms, whereas 3-dimensional conformal radiotherapy was the most commonly used technique (32.4%). 13 Another study of 228 phase 1 radiochemotherapy trials observed comparable results. 14 These 2 studies highlight a significant discrepancy between radiotherapy techniques that are routinely applied in clinical practice and those reported in the literature. Therefore, more well-designed trials are crucial to generate robust clinical evidence that better defines the clinical implementation of novel radiation techniques in the future. Only 763 of 1370 radiotherapy trials (55.7%) were registered before the first participants were enrolled, and this number was significantly lower than that for other oncological trials (16 105 of 24 434 [65.9%]). This delayed registration may have hindered the publication of many radiotherapy trials because they did not comply with registration regulations before enrolling participants, a practice that is adopted widely by many medical journals. 8, 15 To maximize the effect of research, efforts are needed to ensure the timely registration of However, the proportion of radiotherapy trials that had a DMC has decreased in recent years. A DMC is particularly useful for monitoring safety and accrual in clinical trials. However, the appropriate criteria to determine when a DMC is useful or required remain controversial. Consensus is needed to guide researchers when designing trials. Most radiotherapy trials (1340 of 1373 [97.6%]) were conducted in 1 geographic region, which was significantly more common than with other oncological studies (20 405 of 22 552 [90.5%]). Although this finding may be partly attributable to the logistical demands of executing and ensuring robust radiotherapy quality assurance in the setting of a clinical trial, this is nonetheless an important finding because establishing a comprehensive network of global clinical trials would facilitate the gathering of data to enable the most thorough examination of evidence to support medical decision making. 10 Global networks have been or are being established for certain cancer types such as gynecological or head and neck cancers. 16, 17 These efforts will help to accelerate the pace of progress in the treatment of these cancers overall and in radiotherapy in particular.
More important, our analysis of trial recruitment status highlighted 2 key issues. First, early trial stoppages may seem infrequent (approximately 10%) and may seem to occur similarly for both radiotherapy and other oncological trials. However, marginally fewer (but nonetheless statistically signifi- 
Conclusions
This study is a comprehensive overview of radiotherapy trials registered on ClinicalTrials.gov from 2007 to 2017. It highlights the limited number of and the scarcity of funding for radiotherapy trials, which is a concern because of the integral role radiotherapy plays in the clinical management of patients with cancer worldwide. Our findings form the basis for facilitating discussions and collaborations among oncologists, industry leaders, funding agencies, and other concerned parties to promote the conduct of radiotherapy trials that can improve the care of patients with cancer.
